We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSLN
RNS Number : 5612M
Silence Therapeutics PLC
09 January 2019
Silence Therapeutics announces departure of Chief Financial Officer
January 9, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces the departure of Mr. David Ellam, its Chief Financial Officer, with immediate effect. Dr Rob Quinn, Silence Therapeutics' Group Head of Financial Planning and Analysis will serve as interim CFO until a new CFO is appointed.
Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
"On behalf of the Board I would like to thank David for his contribution to Silence. He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 Dr David Horn Solomon, Chief Executive Officer 6900 Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418 James Steel/Oliver Jackson 8900 European IR Tel: +44 (0) 20 Consilium Strategic Communications 3709 5700 Mary-Jane Elliott / Angela Gray silencetherapeutics@consilium-comms.com US IR Tel: +1 (443) 213-0505 Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCDDGDBDXGBGCI
(END) Dow Jones Newswires
January 09, 2019 02:00 ET (07:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
